Santarus Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock Offering Business Wire SAN DIEGO -- May 15, 2013 Santarus, Inc. (NASDAQ: SNTS) today announced the completion of a secondary underwritten public offering of 4,887,500 shares of its common stock, including 637,500 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriter. All shares were offered by Cosmo Technologies Limited at a price to the public of $18.25 per share. Santarus did not sell any shares and will not receive any proceeds from the offering. Jefferies LLC acted as the sole book-running manager for the offering. A shelf registration statement (including a prospectus) relating to these securities was filed by Santarus with the Securities and Exchange Commission (SEC) and declared effective by the SEC on April 29, 2009. A final prospectus supplement and the accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th floor, New York, NY 10022 or by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Santarus Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS^™ ^ (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID^® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists. GLUMETZA^® (metformin hydrochloride extended release tablets) and CYCLOSET^® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and FENOGLIDE^® (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol, are promoted to endocrinologists and other physicians who treat patients with type 2 diabetes. Full prescribing and safety information for Santarus’ products is available at www.santarus.com. Santarus’ product development pipeline includes the investigational drug RUCONEST^® (recombinant human C1 esterase inhibitor). A Biologics License Application for RUCONEST was submitted to the FDA in April 2013 for the treatment of acute angioedema attacks in patients with hereditary angioedema. Santarus is also developing rifamycin SV MMX^®, which is in Phase III clinical testing for the treatment of travelers’ diarrhea. In addition, the company has completed a Phase I clinical program with SAN-300, an investigational monoclonal antibody. More information about Santarus is available at www.santarus.com. Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to risks and uncertainties inherent in Santarus’ business, including, without limitation, difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus’ products and other risks detailed in Santarus’ prior press releases as well as in public periodic filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as may be required by applicable law. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Santarus^®, FENOGLIDE^®, UCERIS^™, and ZEGERID^® are trademarks of Santarus, Inc. GLUMETZA^® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. CYCLOSET^® is a trademark of VeroScience LLC. MMX^® is a trademark of Cosmo Technologies Limited. RUCONEST^® is a trademark of Pharming Group N.V. Contact: COMPANY CONTACT: Martha L. Hough, VP Finance & Investor Relations (858) 314-5824 or Debra P. Crawford, Chief Financial Officer (858) 314-5708 or INVESTOR CONTACT: Westwicke Partners, LLC Stefan Loren, Ph.D. (email@example.com) (858) 356-5930 or Robert Uhl (firstname.lastname@example.org) (858) 356-5932
IBM No Longer Sees Delivering 'at Least $20 Operating EPS' in 2015
Santarus Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock Offering
Press spacebar to pause and continue. Press esc to stop.